Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus

Executive Summary

Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24

You may also be interested in...



Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances

A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products

Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances

A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products

Sandoz To Seek Omnitrope Therapeutic Equivalence With Genotropin

Sandoz plans to submit additional data to FDA to establish therapeutic substitutability for its follow-on human growth hormone product Omnitrope

Related Content

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel